Intraoperative administration of vasopressin during coronary artery bypass surgery is associated with acute postoperative kidney injury

Journal of Critical Care

Volumn 30, Issue 5, 2015, Pages 963-968

  Porhomayon, Jahan ^a   Davari Farid, Sina ^a   Li, Carlos M ^a   Arora, Pradeep ^a   Pourafkari, Leili ^b   Nader, Nader D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute kidney injury; Arginine vasopressin; Coronary bypass surgery; Milrinone; Mortality

Indexed keywords

ARGIPRESSIN; MILRINONE; VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; ADULT; ANTHROPOMETRY; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREVALENCE; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURGICAL MORTALITY; ADVERSE EFFECTS; CASE CONTROL STUDY; CHEMICALLY INDUCED; CORONARY ARTERY BYPASS GRAFT; MIDDLE AGED; ODDS RATIO; PEROPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROCEDURES; RISK FACTOR;

ACUTE KIDNEY INJURY; ARGININE VASOPRESSIN; CARDIOPULMONARY BYPASS; CASE-CONTROL STUDIES; CORONARY ARTERY BYPASS; FEMALE; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; MILRINONE; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS; VASOCONSTRICTOR AGENTS;

EID: 84941318246     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2015.06.013     Document Type: Article

References (44)

1. Albright T.N., Zimmerman M.A., Selzman C.H. Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care 2002, 11(4):326-330. [quiz 331-2].
2. Morales D.L., et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000, 69(1):102-106.
3. Landry D.W., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997, 95(5):1122-1125.
4. Argenziano M., et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997, 96(9 Suppl):II-286-II-290.
5. Jochberger S., et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: a prospective, controlled study. Intensive Care Med 2009, 35(3):489-497.
6. Treschan T.A., Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology 2006, 105(3):599-612. [quiz 639-40].
7. Pulin A.A., et al. Clinical significance of serum and urinary biomarkers for water-salt metabolism in patients with proteinuric forms of chronic glomerulonephritis. Ter Arkh 2014, 86(6):24-29.
8. Ponte B., et al. Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study. J Am Soc Nephrol 2015, 26(6):1415-1425.
9. Dunser M.W., et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome?. Anesth Analg 2004, 99(1):201-206.
10. Dunser M.W., et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001, 93(1):7-13.
11. Jerath N., et al. Clinical impact of vasopressin infusion on hemodynamics, liver and renal function in pediatric patients. Intensive Care Med 2008, 34(7):1274-1280.
12. Moss N.G., Kopple T.E., Arendshorst W.J. Renal vasoconstriction by vasopressin V1a receptors is modulated by nitric oxide, prostanoids, and superoxide but not the ADP ribosyl cyclase CD38. Am J Physiol Renal Physiol 2014, 306(10):F1143-F1154.
13. Harrison-Bernard L.M., Carmines P.K. Juxtamedullary microvascular responses to arginine vasopressin in rat kidney. Am J Physiol 1994, 267(2 Pt 2):F249-F256.
14. Edwards R.M., Trizna W., Kinter L.B. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989, 256(2 Pt 2):F274-F278.
15. Correia A.G., Denton K.M., Evans R.G. Effects of activation of vasopressin-V1-receptors on regional kidney blood flow and glomerular arteriole diameters. J Hypertens 2001, 19(3 Pt 2):649-657.
16. Stewart I.J., Sosnov J.A., Chung K.K. Vasopressin, sepsis, and renal perfusion-a VASST deficit in our understanding. Crit Care Med 2014, 42(6):1583-1584.
17. Guarido K.L., et al. Increased activation of the Rho-A/Rho-kinase pathway in the renal vascular system is responsible for the enhanced reactivity to exogenous vasopressin in endotoxemic rats. Crit Care Med 2014, 42(6):e461-e471.
18. Arora P., et al. Preventable risk factors for acute kidney injury in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2012, 26(4):687-697.
19. Rosner M.H., Okusa M.D. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006, 1(1):19-32.
20. Huen S.C., Parikh C.R. Predicting acute kidney injury after cardiac surgery: a systematic review. Ann Thorac Surg 2012, 93(1):337-347.
21. Arora P., et al. The effect of acute kidney injury after revascularization on the development of chronic kidney disease and mortality in patients with chronic limb ischemia. J Vasc Surg 2015, 61(3):720-727.
22. Ricci Z., Cruz D.N., Ronco C. Classification and staging of acute kidney injury: beyond the RIFLE and AKIN criteria. Nat Rev Nephrol 2011, 7(4):201-208.
23. Russell J.A., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358(9):877-887.
24. Yacoub R., et al. Acute kidney injury and death associated with renin angiotensin system blockade in cardiothoracic surgery: a meta-analysis of observational studies. Am J Kidney Dis 2013, 62(6):1077-1086.
25. Holmes C.L., et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001, 27(8):1416-1421.
26. Patel B.M., et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96(3):576-582.
27. Tsuneyoshi I., et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001, 29(3):487-493.
28. Luckner G., et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005, 33(11):2659-2666.
29. Nygren A., Thoren A., Ricksten S.E. Vasopressin decreases intestinal mucosal perfusion: a clinical study on cardiac surgery patients in vasodilatory shock. Acta Anaesthesiol Scand 2009, 53(5):581-588.
30. Gold J.A., et al. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med 2000, 28(1):249-252.
31. Nishibe S., Tsujita M. The impact of intraoperative vasopressin infusion in complex neonatal cardiac surgery. Interact Cardiovasc Thorac Surg 2012, 15(6):966-972.
32. Rosenzweig E.B., et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999, 100(19 Suppl.):II182-II186.
33. Thakar C.V., et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005, 16(1):162-168.
34. Mehta R.H., et al. Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. Circulation 2006, 114(21):2208-2216. [quiz 2208].
35. Aronson S., et al. Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension. Circulation 2007, 115(6):733-742.
36. Palomba H., et al. Acute kidney injury prediction following elective cardiac surgery: AKICS Score. Kidney Int 2007, 72(5):624-631.
37. Wijeysundera D.N., et al. Derivation and validation of a simplified predictive index for renal replacement therapy after cardiac surgery. JAMA 2007, 297(16):1801-1809.
38. Okamato Y., et al. Vasopressin does not raise cardiac enzymes following cardiac surgery: a randomized double-blind clinical trial. J Cardithorac Vasc Anesth 2015, 29(1):46-51.
39. Argenziano M., et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998, 116(6):973-980.
40. Tayama E., et al. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg 2007, 6(6):715-719.
41. Jeon Y., et al. Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. Eur J Cardiothorac Surg 2006, 29(6):952-956.
42. Papadopoulos G., et al. Perioperative infusion of low-dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-a double-blind randomized study. J Cardiothorac Surg 2010, 5:17.
43. Masetti P., Murphy S.F., Kouchoukos N.T. Vasopressin therapy for vasoplegic syndrome following cardiopulmonary bypass. J Card Surg 2002, 17(6):485-489.
44. Davalos M.C., et al. Hyponatremia during arginine vasopressin therapy in children following cardiac surgery. Pediatr Crit Care Med 2013, 14(3):290-297.